Breaking News

Japan Industrial Production Falls 3.3% in June, More Than Estimated
Tweet TWEET

MERCK SERONO ANNOUNCES COLLABORATION WITH BRISTOL-MYERS (ENG)

     (The following press release from Merck KGaA was received by e-mail. It 
was not confirmed by the sender.) 
News Release 
Your Contact
Phyllis Carter
Phone +49 6151 72-7144 
Merck Serono Announces Collaboration With Bristol-Myers Squibb for
Glucophage in China for Treatment of Type 2 Diabetes 
• Companies focused on expanding access to Glucophage® for patients with
Type
  2 diabetes in China
• Type 2 Diabetes is a growing public health concern in China, with over 90
  million people affected 
Darmstadt, Germany, March 19, 2013 – Merck Serono, a division of Merck in
Darmstadt, Germany, today announced a collaboration for promotion of the
type 2 diabetes drug Glucophage® (metformin hydrochloride) under different
formulations in China. Under terms of the agreement, Merck Serono and
Bristol-Myers Squibb will co-promote Glucophage in China through a
profit-sharing arrangement. Glucophage has been marketed by Bristol-Myers
Squibb-SASS in China since 1999. The two companies will utilize their
existing resources and complementary strengths, with Bristol-Myers
Squibb-SASS continuing to manufacture Glucophage’s IR® (immediate release)
formulation. The collaboration will seek to expand the geographic
distribution of Glucophage as well as provide diabetes-related health and
medical information including education for health professionals. In
addition, the co-promotion will significantly increase outreach to
hospitals. Other terms of the agreement were not disclosed. 
The complete news release can be downloaded at the following link:
http://news.merck.de/N/0/D836A69218EED590C1257B32006AB46C/$File/Chi-Glu-MS.pdf 
News releases from Merck KGaA, Darmstadt, Germany, are available at this
address:
www.merckgroup.com/media or for residents in the USA and Canada at
www.emdgroup.com/media 
In case you are a resident of the USA or Canada please go to
http://www.emdgroup.com/subscribe to register again for your online
subscription of this service as our newly introduced geo-targeting requires
new links in the email. 
Merck KGaA ,Darmstadt, Germany
External Communications
E-mail: Media.Relations@merck.de
Hotline: +49 (0) 6151/72-5000 
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient,
you must not copy this message or attachment or disclose the contents to
any other person. If you have received this transmission in error, please
notify the sender immediately and delete the message and any attachment
from your system. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not accept liability for any omissions or errors in this
message which may arise as a result of E-Mail-transmission or for damages
resulting from any unauthorized changes of the content of this message and
any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
subsidiaries do not guarantee that this message is free of viruses and does
not accept liability for any damages caused by any virus transmitted
therewith. 
Click http://disclaimer.merck.de to access the German, French, Spanish and
Portuguese versions of this disclaimer.